BioCryst Pharmaceuticals’ Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical drug that currently dominates the market, but with less burdensome dosing that could encourage HAE patients to switch.
Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take into clinical trials this year has run into an unexpected hitch: a patent for the compound was awarded to another pharmaceutical company. Biota was granted the patent in “an apparent error,” BioCryst said in a March 12 securities filing. The Feb. 21 patent […]
The investigational hepatitis C treatment under development by BioCryst Pharmaceuticals (NASDAQ:BCRX) is now ready to move into human studies following positive preclinical trial results released today. BioCryst expects to file an investigational new drug application on the compound BCX5191 in the fourth quarter. BioCryst believes BCX5191 can be developed into a drug with once-a-day dosing […]
Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX) board of directors, his second appointment to the board of a North Carolina pharmaceutical company in the last month. In September, Abercrombie was named to the board of Tranzyme Pharma (NASDAQ:TZYM). Both companies are based in Durham, North Carolina. Abercrombie, who has more […]